Form 4: BeiGene CEO John Oyler Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
BeiGene's CEO, John Oyler, executed sales of American Depositary Shares (ADS) on March 12th and 13th, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- John Oyler, CEO of BeiGene, Ltd., reported the sale of American Depositary Shares (ADS) on March 12th and 13th, 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted on December 12, 2023.
- On March 12, 2024, a total of 43,402 ADS were sold at a weighted average price of $162.7378, 15,466 ADS at $163.7793, 12,069 ADS at $164.4877, 2,602 ADS at $165.4876, 733 ADS at $166.4439 and 200 ADS at $169.05.
- On March 13, 2024, a total of 2,737 ADS were sold at a weighted average price of $176.3476, 5,994 ADS at $177.1106, 1,801 ADS at $178.0995, 993 ADS at $179.3276, 307 ADS at $180.2574, 200 ADS at $181.365, 200 ADS at $182.625 and 100 ADS at $184.17.
- Oyler also indirectly owns a significant number of ordinary shares through various trusts and entities, for which he disclaims beneficial ownership.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, reporting the sale of shares by an insider. The sentiment is neutral as it simply reports transactions without expressing any positive or negative views about the company's prospects.
Industry Context
Sales by insiders are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares over a period of time while avoiding concerns about insider trading. It is important to consider the overall context of the company's performance and outlook when evaluating insider sales.
Stakeholder Impact
- Shareholders may react to the news of insider selling, although the existence of a pre-arranged trading plan may mitigate concerns.
- The sales could have a minor impact on the stock price in the short term.
Key Dates
| Date | Description |
|---|---|
| 12/12/2023 | Date of adoption of Rule 10b5-1 trading plan |
| 03/12/2024 | Date of first reported transaction (sale of ADS) |
| 03/13/2024 | Date of subsequent reported transactions (sale of ADS) |
| 03/14/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.